Gene or Genome – Page 4

GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena

2 months ago talkbio0Tagged Analog, Boston Pharmaceuticals, drug acquisition, efimosfermin alfa, fibroblast growth factor 21, Liver diseases, MASH, Phase III, SLC17A5 gene, SmithKline Beecham

GSK; Boston Pharmaceuticals; efimosfermin alfa; Phase III; liver disease; MASH; SLD; drug acquisition; FGF21 analog

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

2 months ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

Revolutions KRAS drugs appear competitive in several lung cancer settings

3 months ago talkbio0Tagged Biological Markers, G12C inhibitors, K-ras Oncogene, KRAZATI, Lumakras, Non-Small Cell Lung Carcinoma, Rotation, sotorasib

KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines

Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit

3 months ago talkbio0Tagged cynicism, Immune response, mandates, Misinformation, Offit, Paul Offit, Urinary hesitation, Vaccines

Vaccines, Urinary hesitation, Offit, cynicism, Misinformation, Immune response, Paul Offit, mandates

Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Dark color, Eli, Eli Lilly, Genome, Haya, Long Intergenic Non-Protein Coding RNA, Obesity

Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

3 months ago3 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

3 months ago talkbio0Tagged cholesterol, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, CTX310, Gene Modification, Genes, In Vivo, LDL Cholesterol Lipoproteins, Triglycerides

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes